{"entity":{"id":"iov-veneto","kind":"institution","name":"Istituto Oncologico Veneto IRCCS","aka":["IOV","Veneto Institute of Oncology"],"tldr":"The Veneto region's OECI-accredited comprehensive cancer centre in Padua, strong in breast cancer trials, melanoma and tumour immunology.","summary":"Founded in 2005, the Istituto Oncologico Veneto is the IRCCS cancer institute of the Veneto region and coordinates the regional oncology network; it is accredited by the OECI as a comprehensive cancer centre. Pierfranco Conte and Valentina Guarneri's breast oncology group led the ShortHER trial of trastuzumab duration and many neoadjuvant studies, the melanoma unit is a leading Italian immunotherapy trial site, and Vincenzo Bronte's immunology programme is known for myeloid-derived suppressor cells. The institute runs gastrointestinal, thoracic and gynaecological oncology, radiotherapy and nuclear medicine across Padua and Castelfranco Veneto, with a phase 1 unit and the University of Padua's oncology school.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.ioveneto.it"},{"label":"Research","url":"https://www.ioveneto.it/ricerca/"}],"tags":[],"related":[],"cancers":["breast-her2-positive","breast-hr-positive","melanoma","colorectal"],"sections":["targeted-therapy","immunotherapy"],"technologies":["monoclonal-antibody","checkpoint-inhibitor","cdk46-inhibitor"],"targets":[],"drugs":["trastuzumab"],"companies":[],"institutions":["oeci","ieo-milan"],"pathways":[],"terms":[],"trials":[],"people":["patrizia-simionato","antonio-rosato"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Padua","country":"IT","lat":45.407,"lng":11.894,"institutionType":"cancer-center","website":"https://www.ioveneto.it","university":"Università degli Studi di Padova","programs":["Breast cancer trials","Melanoma immunotherapy","Tumour immunology (myeloid cells)","Veneto oncology network","Phase 1 unit"]},"route":"/institutions/iov-veneto/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"cdk46-inhibitor","kind":"technology","name":"CDK4/6 inhibitors","route":"/technologies/cdk46-inhibitor/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"institution":[{"id":"ieo-milan","kind":"institution","name":"IEO (European Institute of Oncology)","route":"/institutions/ieo-milan/"},{"id":"oeci","kind":"institution","name":"Organisation of European Cancer Institutes","route":"/institutions/oeci/"}],"person":[{"id":"antonio-rosato","kind":"person","name":"Antonio Rosato","route":"/people/antonio-rosato/"},{"id":"patrizia-simionato","kind":"person","name":"Patrizia Simionato","route":"/people/patrizia-simionato/"}]}}